| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
Oxyepiberberine is natural product of the alkaloid class with various pharmacological effects. It is an alkaloid metabolite found in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease.
| Animal Protocol |
For pharmacokinetic study of ZJ extract containing 8-oxoepiberberine: Male Sprague-Dawley rats (weighing 220-250 g) were orally administered ZJ extract suspended in water at a dose of 3.38 g/kg body weight (equivalent to crude drug dose of 12 g/kg body weight). Blood samples were collected from the suborbital vein at 10, 20, 30, 60, 90, 120, 180, 240, 300, 330, 360, 480, 720, 1440, and 2160 minutes after administration. Plasma was separated by centrifugation at 5000 rpm for 10 minutes and stored at -20°C until analysis [1].
For pharmacokinetic study of FZJ extract containing 8-oxoepiberberine: Male Sprague-Dawley rats (weighing 220-250 g) were orally administered FZJ extract suspended in water at a dose of 3.76 g/kg body weight (equivalent to crude drug dose of 12 g/kg body weight). Blood samples were collected at the same time points (10 to 2160 minutes) from the suborbital vein, centrifuged at 5000 rpm for 10 minutes, and plasma was stored at -20°C until analysis. However, after oral administration of FZJ extract, plasma concentrations of 8-oxoepiberberine at most time points were below the lower limit of quantification (LLOQ), and pharmacokinetic parameters could not be calculated [1]. |
|---|---|
| ADME/Pharmacokinetics |
After oral administration of ZJ extract (at a dose of 3.38 g/kg body weight) to rats, the pharmacokinetic parameters of 8-oxoepiberberine were as follows (mean ± SD, n=6): AUC₀→ₜ = 14.30 ± 2.32 ng·h/mL; AUC₀→∞ = 16.63 ± 3.22 ng·h/mL; MRT₀→ₜ = 450.77 ± 59.37 min; MRT₀→∞ = 740.15 ± 138.92 min; elimination half-life (t₁/₂) = 592.65 ± 274.26 min; observed maximum plasma concentration (Cmax) = 2.38 ± 1.14 ng/mL; time to reach Cmax (Tmax) = 90 min; a secondary peak was observed at 300 min with a concentration (Csec) of 1.85 ± 0.99 ng/mL [1].
The dose-modified systemic exposure level: AUC₀→∞/D = 97.25, Cmax/D = 13.92 (D denotes the dosage of 8-oxoepiberberine in ZJ extract) [1]. After oral administration of FZJ extract, plasma concentrations of 8-oxoepiberberine at most time points were below the LLOQ, so no pharmacokinetic parameters were obtained [1]. The double-peak phenomenon was observed in the plasma concentration-time curve of 8-oxoepiberberine after ZJ administration, with the primary peak at 90 min and a secondary peak at 300 min [1]. 8-oxoepiberberine was not eliminated rapidly in vivo (t₁/₂ ≈ 592 min), suggesting that absorption was the major obstacle to its systemic exposure level [1]. |
| References | |
| Additional Infomation |
8-oxoepiberberine is a tertiary protoberberine alkaloid (TPA) from Coptidis Rhizoma. In the comparative pharmacokinetic study, after oral administration of FZJ extract (with a higher proportion of Euodiae Fructus), the plasma concentrations of 8-oxoepiberberine were below the LLOQ, indicating that the compatibility proportion significantly affected its systemic exposure [1].
The in silico physicochemical property prediction (3PRule) suggested that TPAs like 8-oxoepiberberine have favorable Caco-2 permeability characteristics (PSA ≤ 60, MW ≤ 400, LogD > -1), but their systemic exposure may be limited by lower solubility compared to simple isoquinoline alkaloids [1]. 8-oxoepiberberine was one of the 12 alkaloids quantitatively determined in ZJ and FZJ extracts using an LC-MS/MS method. Its precursor ion (Q1) m/z was 352.2, product ion (Q3) m/z was 308.3, declustering potential (DP) was 105.5 V, and collision energy (CE) was 48.2 eV under positive ionization MRM mode [1]. |
| Molecular Formula |
C20H17NO5
|
|---|---|
| Molecular Weight |
351.3527
|
| Exact Mass |
351.11
|
| CAS # |
19716-60-0
|
| PubChem CID |
12799036
|
| Appearance |
White to yellow solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
603.3±55.0 °C at 760 mmHg
|
| Flash Point |
318.7±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.691
|
| LogP |
3.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])([H])OC2C([H])=C([H])C3C([H])=C4C5=C([H])C(=C(C([H])=C5C([H])([H])C([H])([H])N4C(C=3C1=2)=O)OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
PJTYPIGQKDTERS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17NO5/c1-23-16-8-11-5-6-21-14(13(11)9-17(16)24-2)7-12-3-4-15-19(26-10-25-15)18(12)20(21)22/h3-4,7-9H,5-6,10H2,1-2H3
|
| Chemical Name |
16,17-dimethoxy-5,7-dioxa-1-azapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3(11),4(8),9,12,14,16,18-heptaen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~47.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8462 mL | 14.2308 mL | 28.4616 mL | |
| 5 mM | 0.5692 mL | 2.8462 mL | 5.6923 mL | |
| 10 mM | 0.2846 mL | 1.4231 mL | 2.8462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
